Analysts Have Been Trimming Their Ardelyx, Inc. (NASDAQ:ARDX) Price Target After Its Latest Report
Ardelyx Analyst Ratings
Citi Maintains Ardelyx(ARDX.US) With Buy Rating, Maintains Target Price $10
Scotiabank Maintains Ardelyx(ARDX.US) With Buy Rating, Maintains Target Price $15
BTIG Maintains Ardelyx(ARDX.US) With Buy Rating, Maintains Target Price $14
12 Health Care Stocks Moving In Friday's Intraday Session
Ardelyx Downgraded at Raymond James After Q1 Sales Miss
Ardelyx ARDX Earnings; CytoSorbents CTSO Denied De Novo
Block, Atlassian, Apple, Roku, Amazon And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Analysts Offer Insights on Healthcare Companies: Stryker (SYK), Arvinas Holding Company (ARVN) and Ardelyx (ARDX)
Raymond James Downgrades Ardelyx to Outperform From Strong Buy, Adjusts Price Target to $11 From $13
Scotiabank Remains a Buy on Ardelyx (ARDX)
Express News | Ardelyx Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Financial Results
Ardelyx Price Target Lowered to $10 From $11 at Citi
Why Twilio Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket
TD Cowen Maintains Ardelyx(ARDX.US) With Buy Rating, Cuts Target Price to $10
Earnings Call Summary | Ardelyx(ARDX.US) Q1 2025 Earnings Conference
Ardelyx Targets $240M-$250M in IBSRELA 2025 Sales Amid Strong Q1 Growth
Ardelyx's Growth Potential and Strategic Efforts Justify Buy Rating Despite Recent Setbacks
Compared to Estimates, Ardelyx (ARDX) Q1 Earnings: A Look at Key Metrics